Morales MM,Morales MM

Language: Spanish
References: 25
Page: 108-118
PDF size: 536.66 Kb.

ABSTRACT

Background: chronic obstructive pulmonary disease is mainly characterized by a chronic limitation to little-reversible air flow. Knowing this disease facilitates giving the patients a better quality of life.
Objective: to study the clinical-epidemiological profile of patients in Jardinillos Health Center, in Palencia area, to give them a better quality of life.
Method: a cross-sectional, descriptive, observational study was conducted in 228 patients with the diagnosis of chronic obstructive pulmonary disease from January to December, 2013. A previously structured and codified form for collecting data was used to know the clinical-epidemiological profile. The clinical and epidemiological histories of each patient were revised. Data were analyzed by means of Excel program and the confirmed patients were included.
Results: male patients between 71 and 80 years old predominated. The most seen comorbidity was hypertension and diabetes mellitus; a 61, 8 % of the patients were smokers. Regarding vaccination, a 65, 8 % of the patients were vaccinated against influenza and pneumococcus. The 86 % of the studied patients were negative to alcoholism. The 85, 96 % of the patients presented exacerbation of chronic obstructive disease and required a change in the treatment or admission in the hospital. Most of the patients belonged to the acuter phenotype with chronic bronchitis. The treatment with long-acting bronchodilators was the most used one.
Conclusions: most of the patients were male and of advanced years. The most frequent comorbidity was hypertension and diabetes mellitus and a 61, 8 % of the patients were smokers. The acuter phenotype with chronic bronchitis was the most identified. The treatment with long-acting bronchodilators was the most used one.

REFERENCES

1. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmo-nar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC). Arch Bronconeumol [Internet]. Jun 2012 [citado 30 May 2014];48(Supl 1):1-83[aprox. 2 p.]. Disponible en: http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90141716&pident_usuario=0&pcontactid=&pident_revista=6&ty=92&accion=L&origen=bronco&web=www.archbronconeumol.org&lan=es&fichero=6v48nSupl.1a90141716pdf001.pdf

2. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Guía española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Arch Bronconeumol [Internet]. Jul 2012 [citado 30 May 2014];48(7):247-57:[aprox. 6 p.]. Disponible en: http://www.archbronconeumol.org/es/guia-espanola-epoc-gesepoc-tratamiento/articulo/90141601/ 3. Atkinson W, Hamborsky J, Wolfe S, eds. Epide-miology & Prevention of Vaccine-Preventable Dis-eases. 10th ed. Washington DC: Public Health Foundation; 2008.

3. De la Iglesia Martínez F, Serrano Arreba J, Mon-tes Santiago J. Enfermedad obstructiva crónica (EPOC) y comorbilidades. Galicia Clin [Internet]. 2012 [citado 30 May 2014];73(Supl.1):[aprox. 6 p.]. Disponible en: http://www.galiciaclinica.info/PDF/17/310.pdf

4. Sociedad Española de Medicina de Familia (semFYC), Sociedad Española de Neumología y Ci-rugía Torácica (SEPAR). Grupo de trabajo de la guía de práctica clínica sobre atención integral al paciente con enfermedad pulmonar obstructiva crónica (EPOC) [Internet]. Barcelona: semFYC; 2010 [citado 30 May 2014]. Disponible en: http://www.guiasalud.es/GPC/GPC_468_EPOC_AP_AE.pdf

5. Jithoo A, Enright PL, Burney P, Buist AS, Bate-man ED, Tan WC, et al. BOLD Collaborative Re-search Group. Case-finding options for COPD: re-sults from the Burden of Obstructive Lung Disease study. Eur Respir J. 2013 Mar;41(3):12-6. 7. Steenbruggen I, Zielinski J, Lange P, Price D, Soriano JB. A BOLD statement on how to case-find moderate/severe COPD. Eur Respir J. 2013 Mar;41(3):42-5.

6. García-Olmos L, Alberquilla A, Ayala V, García-Sagredo P, Morales L, Carmona M, et al. Comor-bidity in patients with chronic obstructive pulmo-nary disease in family practice: a cross sectional study. BMC Fam Pract. 2013;14:11.

7. Jamieson DB, Matsui EC, Belli A, McCormack MC, Peng E, Pierre-Louis S, et al. Effects of Allergic Phenotype on Respiratory Symptoms and Exacer-bations in Patients with COPD. Am J Respir Crit Ca-re Med. 2013 Jul 15;188(2):187-92.

8. Jiménez Ruiz CA, Riesco Miranda JA, Altet Gó-mez N, Lorza Blasco JJ, Signes-Costa Miñana J, Solano Reina S, et al. Tratamiento del tabaquismo en fumadores con enfermedad pulmonar obstructi-va crónica. Arch Bronconeumol [Internet]. 2013 [citado 30 May 2014];49(8):[aprox. 6 p.]. Disponi-ble en: http://www.archbronconeumol.org/es/tratamiento-del-tabaquismo-fumadores-con/articulo/90218193/

9. Davis BB, Zeki AA, Bratt JM, Wang L, Filosto S, Walby WF, et al. Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy. Eur Respir J. 2013 Aug;42(2):350-61.

10. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epi-demiological data in Europe: systematic review. BMC Med. 2011 Jan 18;9:2-7.

11. WHO. World health statistics 2008. Geneva: WHO; 2008 [citado 30 May 2014]. Disponible en: http://www.who.int/gho/publications/world_health_statistics/EN_WHS08_Full.pdf?ua=1

12. Regidor E, Gutierrez-Fisac JL, Alfaro M. Patron de mortalidad en Espana, 2008 [Internet]. Ma-drid: Ministerio de Sanidad, Politica Social e Igual-dad; 2011 [citado 30 May 2014]. Disponible en: http://www.msc.es/ca/estadEstudios/estadisticas/estadisticas/estMinisteriO Mortalidad/docs/Patrones_de_Mortalidad_en_Espana_2008.pdf

13. Kohansal R, Martinez–Clambort P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham off spring cohort. Am J Respir Crit Care Med. 2009 Jul 1;180(1):3-10.

14. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective pheno-type? Respir Med. 2013 Jan;107(1):10-22.

15. Garcha DS, Thurston SJ, Patel AR, Mackay AJ, Goldring JJ, Donaldson GC, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012 Dec;67(12):1075-80.

16. 18.Vestbo J, Hurd SS, Agusti AG, Jones PW, Vo-gelmeier C, Anzueto A, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65. 19. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidenced indirectness. J Clin Epidemiol. 2011 Dec;64(12):1303-10.

17. 20.Guyatt GH, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of find-ings tables. J Clin Epidemiol. 2011 Apr;64(4):383-94.

18. Bousquet J, Kiley J, Bateman ED, Viegi G, Cruz AA, Khaltaev N, et al. Prioritised research agenda for prevention and control of chronic res-piratory diseases. Eur Respir J. 2010 Nov;36(5):995-1001.

19. Miravitlles M, Soriano JB, Ancochea J, Muñoz L, Duran-Tauleria E, Sánchez G, et al. Characteri-sation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Res-pir Med. 2013 Jul;107(7):1053-60.

20. Grupo de trabajo GESEPOC. Hacia un nuevo enfoque en el tratamiento de la EPOC.La Guia Es-panola de la EPOC (GESEPOC). Arch Bronconeu-mol [Internet]. Ago 2011 [citado 30 May 2014];47(8):[aprox. 3 p.]. Disponible en: http://www.archbronconeumol.org/es/hacia-un-nuevo-enfoque-el/articulo/90024858/

21. Miravitlles M, Calle M, Soler-Cataluna JJ. Clini-cal phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bron-coneumol. 2012 Mar;48(3):86-98.

22. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmo-nary disease. Lancet. 2009 Aug 29;374(9691):721-32.

23. Estrategia en EPOC del Sistema Nacional de Salud. Plan de Calidad para el Sistema Nacional de Salud [Internet]. Madrid: Ministerio de Sani-dad y Politica Social; 2009 [citado 30 May 2014]. Disponible en: http://www.msssi.gob.es/organizacion/sns/planCalidadSNS/docs/EstrategiaEPOCSNS.pdf

24. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pul-monary disease phenotypes. The future of COPD. Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604.

25. Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cambio. Arch Bronconeumol [Internet]. 2009 Mar [citado 30 May 2014];45(Supl 5):[aprox. 2 p.]. Disponible en: http://www.archbronconeumol.org/es/tratamiento-individualizado-epoc-una-propuesta/articulo-resumen/13148332/